Blog
FDA Approves Giredestrant (Wilserdly): A New All-Oral Option When Breast Cancer Outsmarts Hormone Therapy
On November 16, 2026, the FDA approved giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation. In the evERA trial, the all-oral combination kept cancer from progressing for a median of 10.0 months versus 5.5. Here is who it helps, how the blood test works, and the side effects worth planning for.
Chemotherapy May Age Breast Cancer Survivors Faster, Costing a Modeled 9.4 Years of Life
A new simulation study estimates that breast cancer survivors who received stronger, anthracycline-based chemotherapy could lose a median 9.4 years of life to faster biological aging — while still gaining better protection against the cancer itself. Here is what the model found, and what it cannot prove.
Eating Before Chemo Was Linked to Less Vomiting in a Study of 1,582 Women
In a study of 1,582 women, eating something before a chemotherapy infusion was linked to less vomiting — and, on one regimen, less nausea — especially in the first 24 hours. Here is what the study found, and what it cannot prove.